164 related articles for article (PubMed ID: 32798439)
1. [Research Advance on the Immune Escape of Acute Myeloid Leukemia--Review].
Chen HJ; Zhang S; Luo QD; Li J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1429-1432. PubMed ID: 32798439
[TBL] [Abstract][Full Text] [Related]
2. Natural Killer Immunotherapy for Minimal Residual Disease Eradication Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia.
Hattori N; Nakamaki T
Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31027331
[TBL] [Abstract][Full Text] [Related]
3. Natural killer cell immune escape in acute myeloid leukemia.
Lion E; Willemen Y; Berneman ZN; Van Tendeloo VF; Smits EL
Leukemia; 2012 Sep; 26(9):2019-26. PubMed ID: 22446501
[TBL] [Abstract][Full Text] [Related]
4. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy in acute myeloid leukemia.
Arpinati M; Curti A
Immunotherapy; 2014; 6(1):95-106. PubMed ID: 24341888
[TBL] [Abstract][Full Text] [Related]
6. [Progress and Trend of CAR-T and PD-1 Blockade in the Treatment of Acute Myeloid Leukemia--Review].
Wang JS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Jun; 28(3):1069-1074. PubMed ID: 32552984
[TBL] [Abstract][Full Text] [Related]
7. Advances in immunotherapy for acute myeloid leukemia.
Przespolewski A; Szeles A; Wang ES
Future Oncol; 2018 Apr; 14(10):963-978. PubMed ID: 29542352
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for acute myeloid leukemia (AML): a potent alternative therapy.
Acheampong DO; Adokoh CK; Asante DB; Asiamah EA; Barnie PA; Bonsu DOM; Kyei F
Biomed Pharmacother; 2018 Jan; 97():225-232. PubMed ID: 29091870
[TBL] [Abstract][Full Text] [Related]
9. Advances in immunotherapy for pediatric acute myeloid leukemia.
Bonifant CL; Velasquez MP; Gottschalk S
Expert Opin Biol Ther; 2018 Jan; 18(1):51-63. PubMed ID: 28945115
[TBL] [Abstract][Full Text] [Related]
10. Larger Size of Donor Alloreactive NK Cell Repertoire Correlates with Better Response to NK Cell Immunotherapy in Elderly Acute Myeloid Leukemia Patients.
Curti A; Ruggeri L; Parisi S; Bontadini A; Dan E; Motta MR; Rizzi S; Trabanelli S; Ocadlikova D; Lecciso M; Giudice V; Fruet F; Urbani E; Papayannidis C; Martinelli G; Bandini G; Bonifazi F; Lewis RE; Cavo M; Velardi A; Lemoli RM
Clin Cancer Res; 2016 Apr; 22(8):1914-21. PubMed ID: 26787753
[TBL] [Abstract][Full Text] [Related]
11. Interferon-induced programmed death-ligand 1 (PD-L1/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment.
Krönig H; Kremmler L; Haller B; Englert C; Peschel C; Andreesen R; Blank CU
Eur J Haematol; 2014 Mar; 92(3):195-203. PubMed ID: 24175978
[TBL] [Abstract][Full Text] [Related]
12. The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatment.
Isidori A; Salvestrini V; Ciciarello M; Loscocco F; Visani G; Parisi S; Lecciso M; Ocadlikova D; Rossi L; Gabucci E; Clissa C; Curti A
Expert Rev Hematol; 2014 Dec; 7(6):807-18. PubMed ID: 25227702
[TBL] [Abstract][Full Text] [Related]
13. Early evaluation of natural killer activity in post-transplant acute myeloid leukemia patients.
Pittari G; Fregni G; Roguet L; Garcia A; Vataire AL; Wittnebel S; Amsellem S; Chouaib S; Bourhis JH; Caignard A
Bone Marrow Transplant; 2010 May; 45(5):862-71. PubMed ID: 19802033
[TBL] [Abstract][Full Text] [Related]
14. Acute myeloid leukaemia and the immune system: implications for immunotherapy.
Barrett AJ
Br J Haematol; 2020 Jan; 188(1):147-158. PubMed ID: 31782805
[TBL] [Abstract][Full Text] [Related]
15. An overview of the potential strategies for NK cell-based immunotherapy for acute myeloid leukemia.
Sinha C; Cunningham LC
Pediatr Blood Cancer; 2016 Dec; 63(12):2078-2085. PubMed ID: 27535002
[TBL] [Abstract][Full Text] [Related]
16. The progress and current status of immunotherapy in acute myeloid leukemia.
Yang D; Zhang X; Zhang X; Xu Y
Ann Hematol; 2017 Dec; 96(12):1965-1982. PubMed ID: 29080982
[TBL] [Abstract][Full Text] [Related]
17. Natural killer cell allorecognition of missing self in allogeneic hematopoietic transplantation: a tool for immunotherapy of leukemia.
Velardi A; Ruggeri L; Mancusi A; Aversa F; Christiansen FT
Curr Opin Immunol; 2009 Oct; 21(5):525-30. PubMed ID: 19717293
[TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
19. Cytokine-Induced Memory-Like NK Cells: Emerging strategy for AML immunotherapy.
Bakhtiyaridovvombaygi M; Yazdanparast S; Mikanik F; Izadpanah A; Parkhideh S; Shahbaz Ghasabeh A; Roshandel E; Hajifathali A; Gharehbaghian A
Biomed Pharmacother; 2023 Dec; 168():115718. PubMed ID: 37857247
[TBL] [Abstract][Full Text] [Related]
20. How important is NK alloreactivity and KIR in allogeneic transplantation?
Shaffer BC; Hsu KC
Best Pract Res Clin Haematol; 2016 Dec; 29(4):351-358. PubMed ID: 27890259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]